Cook Meredith sold $41K of ANIP

Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) sold 500 shares of ANI PHARMACEUTICALS INC (ANIP) at $82.03 on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Meredith
Published Jun 15, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not introduce new company fundamentals or guidance.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure reduces the likelihood of a strong price catalyst.

03

What to watch

The article provides only one sale lot size and does not indicate whether there were concurrent buys, option exercises, or changes in broader insider activity.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-06-15 after the 2026-06-12 sale date

Background

The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, Inc.

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

SEC Form 4 shows ANIP’s General Counsel sold 500 shares on 2026-06-12 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new company-specific catalysts.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory development disclosed.

Market effects

No sector read-across; this is a single-company insider transaction with no stated business change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still watch for follow-on disclosures.

Key entities

  • ANI Pharmaceuticals, Inc.

    Subject of the SEC Form 4 insider transaction disclosure (ANIP).

  • Cook Meredith

    Senior VP, General Counsel & SEC; reported an open-market sale of 500 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIPHighAI 9/10

ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth

ANI Pharmaceuticals (ANIP) reported Q3 2026 revenue of $290.8M (+28% YoY) and raised 2026 guidance. CEO Lalwani discussed a $560M cash offer for Aegidus Therapeutics, funded by cash and debt. Emcitate's U.S. pricing set at $74,026 per pack. Cortrophin demand exceeded expectations, causing temporary pharmacy bottlenecks. The company aims to expand prescriber base and identify more MCT8 deficiency patients.

$ANIPHighAI 8/10

ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharma (ANIP) reported Q3 2026 revenue of $290.8M, up 28% YoY, with adjusted EBITDA of $82.3M, up 40% YoY. Rare disease revenues grew 36% YoY, while generics grew 11%. The company revised Cortrophin Gel revenue guidance to $480M-$500M for 2026, down from $520M-$540M, citing supply chain issues. ANIP also announced an offer to acquire Aegidus Therapeutics, aiming to expand its rare disease portfolio.

$ANIPHighAI 8/10

ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals reported Q3 revenue of $104.5M, up 11% YoY. The company announced a $434M acquisition of Egetis, adding rare disease drug EMCITATE, expected to close in late 2026. ANI raised its 2026 revenue forecast to $1.085B-$1.125B and expects EMCITATE to generate over $300M in peak sales. The company has $420.8M in cash and $616.9M in debt.

$ANIPHigh

ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026

ANI Pharmaceuticals reported Q3 2026 revenue of $290.8M, beating estimates by 4.3% and growing 27.6% YoY. Adjusted EPS of $2.70 beat estimates by 23.8%. The company reconfirmed its revenue guidance of $1.11B and raised its adjusted EPS guidance to $9.54. EBITDA guidance was set at $295M, above consensus. Operating margin increased to 18% from 15.9% YoY.